Bans Some Anti - Depressant Ads
By THE ASSOCIATED PRESS
at 10:19 a.m. ET
ANGELES (AP) -- A federal judge ordered the maker of the popular
anti-depressant Paxil to halt all television commercials nationwide
that claim the drug is not habit-forming.
ruling against GlaxoSmithKline comes about a year after a class-action
lawsuit was filed on behalf of 35 patients who claimed they suffered
withdrawal symptoms such as nausea, fever, and ``electric zaps''
to their bodies.
District Judge Mariana Pfaelzer found that in other countries,
labels on the drug warn of adverse reactions when use of the drug
commercials were ``misleading and created inaccurate expectations
about the ease of withdrawal from the drug,'' Pfaelzer ruled Monday.
attorneys are appealing.
U.S. Food and Drug Administration -- and not the courts -- has
the expertise and responsibility for reviewing and regulating
pharmaceutical ads,'' David Stout, president of U.S. Pharmaceuticals
at Paxil's producers,
GlaxoSmithKline, said in a statement.
Paxil television ad was submitted for FDA review prior to use,
and the agency raised no objections to the language at issue,''
plaintiffs' lead attorney, Karen Barth, said GlaxoSmithKline changed
its labeling on Dec. 14 but continued to run commercials and distribute
brochures saying Paxil ``may cause mild, usually temporary side
effects in some individuals.''
attorneys said a hearing was set for Oct. 7 to decide whether
the lawsuit should be converted to a nationwide class-action.
ads also said ``Paxil has been studied both in short-term and
long-term use and is not associated with dependence and addiction.''
U.S. sales of Paxil and the asthma drug Advair led a 15 percent
increase in second-quarter profits for London-based GlaxoSmithKline
PLC. Global sales of Paxil grew 29 percent.